Prime Medicine, Inc.
About Prime Medicine, Inc.
Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Its program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported by preclinical data showing targeted correction and restoration of copper homeostasis in animal models. In addition, PM647 is being developed for alpha-1 antitrypsin deficiency, or AATD, another liver targeted disease with substantial unmet need.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $4.6M
- Net income
- -$201.1M
- Total assets
- $342.7M
- Market cap
- $552.7M
- Operating margin
- -4498.1%
- Net margin
- -4342.4%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $4.6M
- Operating expenses
- $213.0M
- Operating income
- -$208.3M
- Income tax
- $0
- Net income
- -$201.1M
- EPS (basic)
- $-1.35
- EPS (diluted)
- $-1.35
Balance sheet
- Total assets
- $342.7M
- Current assets
- $181.3M
- Total liabilities
- $221.9M
- Current liabilities
- $37.4M
- Shareholders’ equity
- $120.9M
Cash flow
- Operating cash flow
- -$162.6M
- Investing cash flow
- -$108.8M
- Financing cash flow
- $151.5M
- Net cash flow
- -$119.8M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $552.7M
- EPS (diluted)
- $-1.35
- Dividend yield
- 108.11%
- Shares outstanding
- 186.7M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Oct 20, 2022
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $201.1M in FY2025.
- Trading 56% below its 52-week high.
- Pays a dividend yielding about 108.11% annually.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
Peers & competitors
No reviews yet. Be the first to review Prime Medicine, Inc..
Write a review
News about Prime Medicine, Inc.
News & sentiment via Polygon.io
